THE FAMILY DOCTOR’S ROLE IN ACHIEVING TARGET LEVELS OF TREATMENT IN PATIENTS WITH TYPE 2 DIABETES
Keywords:type 2 diabetes mellitus, dyslipidemia, arterial hypertension
The aim of the study was to identify the proportion of patients with type 2 diabetes who were unable to
achieve the triple treatment goal for concomitant control of blood glucose level, blood pressure, LDL and modifying factors associated with achieving triple therapy goals. The study included 675 patients with type 2 diabetes,
dyslipidemia and hypertension. The analysis was performed using concurrent triple treatment goals with specific levels of HbA1c, LDL and blood pressure as the main result. The questionnaire for patients with dyslipidemia
included self-assessment of compliance with prescribed drugs and perceptions related to their understanding
and attitude towards lifestyle changes and pharmacological treatment. The results of the analysis of the logistic regression of factors associated with the achievement of triple treatment goals showed that patients who
received moderate doses of statins with high intensity were less likely to achieve concurrent treatment of the
goal compared to low intensity. Younger patients were less likely to achieve the triple treatment goal than those
over 60 years of age. Based on life expectancy, they will be more susceptible to vascular complications due to an
earlier onset of the disease and a longer period of time during which these adverse events can develop. Fewer
drugs and a shorter duration of type 2 diabetes were significant factors in the triple control. It was proved that
simultaneous control of glycemia, hypertension and lipids was achieved in 22.4% of patients, who were affected
by the intensity of statin treatment, the number of diabetic drugs and the presence of concomitant pathology.
Thus, the simultaneous achievement of the triple goal is a more comprehensive mitigation measure to reduce the
risk of both macro- and microvascular complications
Brownrig JR, Hughes CO, Burleigh D, et al. Lancet Diabetes Endocrinol 2016; 4(7): 588-597. doi: http://doi.org/10.1016/ S2213-8587(16)30057-2.
American Diabetes Association. Diabetes Care. 2019; 42(1):S103-S123. Doi: http://doi.org/10.2337/Dc19-S010.
Expert C, Punthakee Z, Goldenberg R, et al. Can J Diabetes 2018; 42(1):S10-S15. doi: http://doi.org/ 10.1016/j.jcjd.2017.10.003.
Force M, Ryden L, Grant PJ, et al. Eur Heart J 2013; 34(39): 3035-3087. doi: http://doi.org/10.1093/eurheartj/eht108.
Piepoli MF, Hoes AW, Agewall S, et al. Eur Heart J 2016; 37(29): 2315-2381. doi: http://doi.org/10.1093/eurheartj/ehw106.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Diabetes Care 2012; 35(6): 1364-1379. doi: http://doi.org/10.2337/dc12-0413.
Jellinger PS, et al. Endocr Pract 2017; 23(2): 1-87. doi: http://doi.org/ 10.4158/EP171764.APPGL.
Feingold KR, Grunfeld C. Obesity and Dyslipidemia, South Dartmouth, 2018.
Enkhmaa B, et al. Lifestyle Changes: Effect of Diet, Exercise, Functional Food, and Obesity Treatment, on Lipids and Lipoproteins, South Dartmouth, 2018.